PRECISION BIOSCIENCES INC - Common Stock, par value $0.000005 per share (DTIL)
CUSIP: 74019P207
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, par value $0.000005 per share
- Shares outstanding
- 24,241,780
- Total 13F shares
- 15,096,207
- Share change
- +8,251,010
- Total reported value
- $62,794,720
- Price per share
- $4.16
- Number of holders
- 67
- Value change
- +$33,303,415
- Number of buys
- 40
- Number of sells
- 15
Quarterly Holders Quick Answers
What is CUSIP 74019P207?
CUSIP 74019P207 identifies DTIL - PRECISION BIOSCIENCES INC - Common Stock, par value $0.000005 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74019P207:
Top shareholders of DTIL - PRECISION BIOSCIENCES INC - Common Stock, par value $0.000005 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Octagon Capital Advisors LP |
13D/G
|
— |
10%
|
2,328,485
|
$9,570,073 | $0 | 31 Dec 2025 | |
| Empery Asset Management, LP |
13D/G
|
— |
10%
|
2,297,781
|
$9,558,769 | $0 | 31 Dec 2025 | |
| Aberdeen Group plc |
13D/G
|
— |
8.9%
|
2,138,603
|
$8,896,588 | $0 | 31 Dec 2025 | |
| Bleichroeder LP |
13D/G
13F
|
Company |
8.2%
|
1,900,000
|
$7,809,000 | +$3,390,750 | 31 Dec 2025 | |
| Lynx1 Capital Management LP |
13F
13D/G
|
Company |
4.1%
from 13D/G
|
1,042,596
|
$5,755,130 | — | 30 Sep 2025 | |
| Readout Capital, LP |
13D/G
|
Matthew Smith |
9.4%
|
1,119,311
|
$4,980,934 | +$829,645 | 30 Jun 2025 | |
| NOVARTIS PHARMA AG |
3/4/5
13D/G
|
10%+ Owner |
3.7%
from 13D/G
|
12,407,440
|
$4,590,753 | — | 15 Jun 2022 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.7%
|
653,649
|
$3,608,142 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2%
|
492,596
|
$2,719,130 | — | 30 Sep 2025 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13D/G
|
— |
3.7%
|
406,250
|
$2,165,312 | $0 | 31 Mar 2025 | |
| Weinstein Benjamin |
13D/G
|
— |
5.2%
|
395,489
|
$2,107,956 | $0 | 18 Mar 2025 | |
| Derek Jantz |
3/4/5
|
Chief Scientific Officer, Director |
—
mixed-class rows
|
4,079,565
mixed-class rows
|
$1,509,439 | — | 07 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.81%
|
196,177
|
$1,082,897 | — | 30 Sep 2025 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.74%
|
178,535
|
$985,513 | — | 30 Sep 2025 | |
| Matthew R. Kane |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
2,026,513
mixed-class rows
|
$749,324 | — | 07 Jun 2021 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.49%
|
119,359
|
$658,000 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
109,521
|
$604,598 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.41%
|
98,699
|
$544,819 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.34%
|
83,092
|
$458,668 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.26%
|
61,901
|
$341,694 | — | 30 Sep 2025 | |
| Quarry LP |
13F
|
Company |
0.24%
|
59,375
|
$327,750 | — | 30 Sep 2025 | |
| Tejara Capital Ltd |
13F
|
Company |
0.24%
|
58,752
|
$324,311 | — | 30 Sep 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.23%
|
55,845
|
$308,000 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.21%
|
52,024
|
$287,172 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.18%
|
43,641
|
$240,898 | — | 30 Sep 2025 | |
| Kevin Buehler |
3/4/5
|
Director |
—
mixed-class rows
|
49,137
mixed-class rows
|
$234,961 | +$21,116 | 25 Jun 2025 | |
| Melinda Brown |
3/4/5
|
Director |
—
mixed-class rows
|
44,346
mixed-class rows
|
$233,941 | +$20,673 | 15 Dec 2025 | |
| Geno J. Germano |
3/4/5
|
Director |
—
mixed-class rows
|
44,883
mixed-class rows
|
$230,639 | +$14,160 | 16 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.16%
|
38,142
|
$210,544 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.16%
|
38,067
|
$210,130 | — | 30 Sep 2025 | |
| Stanley R. Frankel |
3/4/5
|
Director |
—
mixed-class rows
|
40,478
mixed-class rows
|
$209,458 | +$26,109 | 16 Dec 2025 | |
| Shari Lisa Pire |
3/4/5
|
Director |
—
mixed-class rows
|
35,028
mixed-class rows
|
$189,875 | — | 27 May 2025 | |
| Samuel C. Wadsworth |
3/4/5
|
Director |
—
mixed-class rows
|
14,028
mixed-class rows
|
$161,277 | — | 04 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.1%
|
24,476
|
$135,107 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.09%
|
22,142
|
$122,224 | — | 30 Sep 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.08%
|
20,000
|
$110,400 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.07%
|
17,722
|
$98,000 | — | 30 Sep 2025 | |
| Virtu Financial LLC |
13F
|
Company |
0.06%
|
15,166
|
$84,000 | — | 30 Sep 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.06%
|
13,971
|
$77,120 | — | 30 Sep 2025 | |
| Vanguard Personalized Indexing Management, LLC |
13F
|
Company |
0.05%
|
13,127
|
$72,461 | — | 30 Sep 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.05%
|
12,041
|
$66,466 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.04%
|
10,474
|
$57,817 | — | 30 Sep 2025 | |
| Alan List |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
5,469
mixed-class rows
|
$56,440 | — | 01 May 2024 | |
| Corient Private Wealth LLC |
13F
|
Company |
0.04%
|
10,000
|
$55,200 | — | 30 Sep 2025 | |
| Miller Financial Services LLC |
13F
|
Company |
0.04%
|
10,000
|
$55,200 | — | 30 Sep 2025 | |
| NATIONAL BANK OF CANADA /FI/ |
13F
|
Company |
0.03%
|
7,575
|
$41,360 | — | 30 Sep 2025 | |
| David S. Thomson |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
130,768
mixed-class rows
|
$41,260 | — | 23 Jun 2021 | |
| Allworth Financial LP |
13F
|
Company |
0.02%
|
4,769
|
$26,325 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.02%
|
4,675
|
$25,806 | — | 30 Sep 2025 | |
| Shane Barton |
3/4/5
|
VP & Corporate Controller |
—
mixed-class rows
|
33,562
mixed-class rows
|
$12,418 | — | 07 Jun 2023 |
Institutional Holders of PRECISION BIOSCIENCES INC - Common Stock, par value $0.000005 per share (DTIL) as of Q4 2025
As of 31 Dec 2025,
PRECISION BIOSCIENCES INC - Common Stock, par value $0.000005 per share (DTIL) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,096,207 shares.
The largest 10 holders included
Empery Asset Management, LP, Aberdeen Group plc, Octagon Capital Advisors LP, Bleichroeder LP, BOOTHBAY FUND MANAGEMENT, LLC, Lynx1 Capital Management LP, VANGUARD GROUP INC, Alyeska Investment Group, L.P., Driehaus Capital Management LLC, and SPHERA FUNDS MANAGEMENT LTD..
This page lists
67
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
54
Q4 2025 holders
67
Holder diff
13
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.